Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

66.98 +2.29 (+3.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
From Exact Sciences Corp.
Via Business Wire
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
3 Growth Stocks to Buy at 52-Week Lows in March
Wager on these growth stocks to buy at 52-week lows offering robust investment potential ahead for savvy investors. 
Via InvestorPlace
2 Beaten-Down Cathie Wood Stocks With Massive Potential
They won't lag the market forever. 
Via The Motley Fool
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Earnings Preview For Exact Sciences
 
Via Benzinga
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
From Exact Sciences Corp.
Via Business Wire
Cathie Wood Darling Exact Sciences Could Pop After Its Next-Gen Product Outperforms
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025. 
Via Investor's Business Daily
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
From Exact Sciences Corp.
Via Business Wire
Cathie Wood Is Selling This Stock: Should You?
This company hasn't performed well in the past 12 months. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
7 Stable Stocks to Buy for 100% Returns by 2025
If you're looking for stability and the opportunity to double your returns by the time 2025 rolls around, check out these stable stocks. 
Via InvestorPlace
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
While these underdogs stocks might not be on everyone’s radar, they may offer surprisingly robust upside potential. 
Via InvestorPlace
3 Hot Stocks Bought by Members of Congress: Follow the Money
Palo Alto Networks, Simon Property Group and JPMorgan Chase are the top three stocks bought by Members of Congress in February; 
Via MarketBeat
Exact Sciences to Participate in March Investor Conference
From Exact Sciences Corp.
Via Business Wire
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Market participants remain attentive to several factors shaping the day's trading landscape, including scheduled Fed speeches, weekly jobless claims data, and private-sector activity readings. 
Via Benzinga
Topics Economy Stocks
Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript
EXAS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exact Sciences Announces Fourth Quarter 2023 Results
From Exact Sciences Corp.
Via Business Wire
Wall Street Waits With Bated Breath For Nvidia Earnings After Tech Selloff, Fed Minutes Eyed: Analyst Flags This As Biggest Risk For Market
The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said. 
Via Benzinga
Topics Economy
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
--News Direct-- 
Via News Direct
Topics Death
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the... 
Via Benzinga
Topics Death
Exact Sciences Schedules Fourth Quarter 2023 Earnings Call
From Exact Sciences Corp.
Via Business Wire
3 Stocks to Buy for the Age of Personalized Medicine
Personalized medicine stocks can unlock significant growth from your portfolio. Here are three companies to consider. 
Via InvestorPlace
2 Cathie Wood Growth Stocks to Buy and Hold for the Long Haul
These stocks can reward patient investors. 
Via The Motley Fool
The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market
With the value of the cancer testing market expected to soar over the next decade, here are the three best disease testing stocks to buy now. 
Via InvestorPlace
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.